

**Virginia Medicaid Preferred Drug List (PDL) Program:
Annual Review of PDL Phase II and Review of New Drugs
Pharmacy and Therapeutics Committee Meeting
Tuesday, April 17, 2007
9:00 a.m., 7th Floor Conference Rooms
DRAFT AGENDA**

**Welcome and Comments from
DMAS' Director**

**Patrick Finnerty,
DMAS Director**

Comments from the Chairperson

**Randy Axelrod, M.D.,
Chairman**

**Acceptance of Minutes From
October 23, 2006 P&T Meeting**

P&T Committee Members

**Review of Proton Pump Inhibitors
(PPI) Drug Class**

**Randy Axelrod, M.D.,
Chairman**

Drug Class Discussions

P&T Committee Members

Review of New Drugs in PDL Phase I

- Coreg CR - Beta Blockers
- Oxybutynin Chloride ER – Urinary Tract Antispasmodics

Phase II PDL Annual Review

Diabetes - Oral Hypoglycemics

- Second Generation Sulfonylureas
- Alpha-Glucosidase Inhibitors
- Biguanides,
- Biguanide Combination Products
- Meglitinides
- Thiazolidinediones)

Asthma/allergy

- Leukotriene Modifiers

Analgesics

- Non-Steroidal Anti- Inflammatory Drugs (NSAID) (*now includes Cox-2 Inhibitors*)
- Long Acting Narcotics

Central Nervous System

- Antihyperkinesia/CNS Stimulants (Medications for ADD/ADHD)

Osteoporosis

- Bisphosphonates

Antibiotics/Anti-Infectives

- Second Generation Cephalosporins
- Third Generation Cephalosporins

- Second Generation Quinolones Systemic
- Third Generation Quinolones – Systemic
- Macrolides - Adult and Pediatric
- Oral Antifungals for Onychomycosis

Antivirals

- Herpes
- Influenza

Ophthalmic

- Alpha-2 Adrenergic
- Beta-blockers
- Carbonic Anhydrase Inhibitors
- Prostaglandin Inhibitors
- Anti-Inflammatory
- Quinolones
- Antihistamines
- Mast Cell Stabilizers

Miscellaneous

- Serotonin Receptor Agonists (Triptans)

Confidential Meeting

Confidential Meeting for
P&T Committee Members,
DMAS, and FHSC Pursuant to
42 U.S.C. § 1396r-8 to discuss
pricing information

Criteria Discussion of Phase I New Drugs*

P&T Committee Members

Criteria Discussions for PDL Phase II Drug Classes*

P&T Committee Members

Next Meeting – TBD

Randy Axelrod, M.D.,
Chairman

**Criteria discussions will be held for classes only if deemed PDL eligible by the P&T Committee during Drug Class Discussions*

Oral presentations: The P&T Committee in conjunction with the Department will be allocating time slots for interested parties to present scientific and clinical information on *only* the drug classes subject to PDL Phase II annual review and specific new drugs in PDL Phase I classes listed on the Agenda. All presentations must include newly published information (per guidelines below) that is clinical in nature and based on scientific material. The references used to authorize presentations must be within the following timeframes:

- PDL Phase II Annual Review – March 2006 to present
- New Drugs in PDL Phase I Drug Classes – October 2005 to present

No anecdotal accounts are to be given. Each speaker will be allocated no more than 3 minutes to present. The actual speakers will be decided by the Chairperson based on relevancy of the information. Speakers must receive a confirmation number to verify the presentation is scheduled.

If you are interested in providing specific clinical information to the Committee at the meeting, please submit an outline of discussion points, clinical references (within the stated guidelines above) and a written request to speak with the name/title of the presenter. Please send information to pdlinput@dmass.virginia.gov by COB Tuesday, March 27, 2007.

Written information/comments: The P&T Committee will also accept written comments for consideration. Please send statements to pdlinput@dmass.virginia.gov by COB Tuesday, March 27, 2007.